Benproperine selectively inhibits the migration and invasion of cancer cells by targeting and inhibiting the function of the ARPC2 subunit, and, interestingly, Benproperine does not affect the expression levels of the Arp2/3 complex subunit or the migration of normal cells.[61,62] Thus, small molecule inhibitors that target the Arp2/3 complex subunit and impair its function may be a new avenue for cancer therapy, and evidence suggests that ARPC2 is also a promising potential target for cancer diagnosis and treatment. Here, ACTR2 is linked to cancer.